ArticleThe Journal of clinical investigation2015
CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.
Article in The Journal of clinical investigation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Aptamers and aptamer-drug conjugates as synthetic immune modulators for cancer immunotherapy.Frontiers in immunology · 2026Review
- The NR_109/FUBP1/c-Myc axis regulates TAM polarization and remodels the tumor microenvironment to promote cancer development.Journal for immunotherapy of cancer · 2023Article
- A cellular census of human peripheral immune cells identifies novel cell states in lung diseases.Clinical and translational medicine · 2021Article
- Blocking leptin-STAT3 axis-induced fatty acid oxidation: A novel approach to activate CD8Thoracic cancer · 2020Article
- Combined Targeting of Glioblastoma Stem-Like Cells by Neutralizing RNA-Bio-Drugs for STAT3.Cancers · 2020Article
- Integrin α6 signaling induces STAT3-TET3-mediated hydroxymethylation of genes critical for maintenance of glioma stem cells.Oncogene · 2020Article
- STAT3 Activation-Induced Fatty Acid Oxidation in CD8Cell metabolism · 2020Article
- STAT3 Gene Silencing by Aptamer-siRNA Chimera as Selective Therapeutic for Glioblastoma.Molecular therapy. Nucleic acids · 2018Article
- L61H46 shows potent efficacy against human pancreatic cancer through inhibiting STAT3 pathway.Cancer management and research · 2018Article
- A CTLA-4 Antagonizing DNA Aptamer with Antitumor Effect.Molecular therapy. Nucleic acids · 2017Article
Corrections and comments
- Erratum forCTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.2014 · Swiderski, Piotr [Added]
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.